United States  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug

Proactive Investors Thursday, 12 September 2019
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ: KZIA) has revealed that St Jude Children’s Research Hospital successfully completed the first stage of its ongoing phase I study of Kazia’s investigational new drug, GDC-0084 in diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas. Diffuse midline gliomas, including DIPG, represent one of the most aggressive childhood cancers, and several hundred new cases are diagnosed in the US each year. Median life expectancy from diagnosis is estimated to be 9-11 months, and there is no approved pharmacological therapy. St Jude hospital’s study has determined an appropriate dose for paediatric use and will now advance into the second stage of the study, which is designed to explore preliminary signals of efficacy in this disease. Early signs are encouraging Co-lead investigator on the study Dr. Christopher Tinkle said: “To date, thirteen patients have received GDC-0084 in our study. “We have determined a maximum tolerated dose (MTD) in the pediatric setting of 27 mg/m2 , which we would expect to be approximately equivalent to the doses currently being explored in adult studies. “The safety profile of the drug in children appears to be broadly similar to that in adults, and we have encountered no unexpected findings in this regard. “It would be premature to draw conclusions regarding potential efficacy, but we now embark on an expansion cohort to explore the clinical effects of the drug in this patient group. “My colleagues and I are very pleased with progress and look forward to reporting further data from the study.” Acceptable tolerability profile Kazia CEO Dr James Garner said: “DIPG is a devastating illness with a poor prognosis and a paucity of effective treatments. It has been a privilege to support the St Jude team on this incredibly important project. “The study has recruited well ahead of our expectations, and we are delighted to have the first part successfully completed. “Toxicity can be a significant challenge in the treatment of childhood cancer, so it is very encouraging that GDC-0084 appears to have an acceptable tolerability profile. We are excited to see further data in due course.”
0
shares
ShareTweetSavePostSend
 
Credit: CBS4 Miami - Published < > Embed
News video: Hyundai Hope On Wheels Awards Grant To Sylvester For Pediatric Research

Hyundai Hope On Wheels Awards Grant To Sylvester For Pediatric Research 00:44

The $300,000 grant to help fund research to find a cure for childhood cancer.

You Might Like


Recent related videos from verified sources

Homeowners get 'Prowler Panic' From a Possible Intruder This Many Times a Year [Video]Homeowners get 'Prowler Panic' From a Possible Intruder This Many Times a Year

American homeowners experience the heart-pumping fear that someone might be breaking into their home four times a year, according to a new study examining the home security routines and worries of..

Credit: SWNS STUDIO     Duration: 01:27Published

Study Finds More Americans are Experimenting With Alternative Wellness Remedies [Video]Study Finds More Americans are Experimenting With Alternative Wellness Remedies

Eight in 10 Americans have made a 'U-turn' in their opinions surrounding cannabis and marijuana usage, according to a new survey. A study of 2,000 Americans saw 82 percent agree with the sentiment that..

Credit: SWNS STUDIO     Duration: 01:02Published


Recent related news from verified sources

London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
*TORONTO, ON / ACCESSWIRE / **October **7, 2019 /* Theralase® Technologies Inc. ("*Theralase*" or the "*Company*") (*TSXV:TLT*)(*OTCQB:TLTFF*), a clinical stage...
Accesswire

Genprex believes in non-viral delivery as the next evolution in gene therapy, and scientific paper agrees

Genprex Inc (NASDAQ:GNPX), a company developing non-viral delivery for gene therapy in cancer treatments, said Monday that a recently published scientific paper...
Proactive Investors

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.